Medochemie launches Rovasta in Jordan

Medochemie held a very successful launch event in Jordan for the market introduction of Rovasta (Rosuvastatin Calcium), its newest addition to the company’s rich portfolio on cardiovascular chronic diseases therapeutic area.

Around 100 of the top health care professionals in the country, from private and public sector, including Cardiologists, Endocrinologists and Internal Medicine Specialists, representatives of the relative Medical Associations, key officials from the Royal Medical Services (DRMS) and hospital procurement managers attended the event. They all had the opportunity to hear the latest scientific data available on the molecule whilst also share experience from actual clinical practice.

The renowned Interventional Cardiologist and Senior Consultant Dr. Osma Okkeh, member of the Jordanian Atherosclerosis and Hypertension Society (JAHS), presented the up-to-date practices on dyslipidemia management. His speech entitled “Rosuvastatin… basics and updates“ focused on how targets for patients with dyslipidemia can timely and efficiently be achieved as well as on how this eventually provides them with a better quality of life.

Medochemie’s vision for Jordan and the whole of MENA region in coming years, is to keep expanding its portfolio and fully meeting the needs in multiple therapeutic areas while contributing in making a difference in people’s health, always committed to product quality and patient safety.